BaseSpace
Import Your Data
Literature

FAQ

More FAQs

Back to top
Clear Search sequence regions
(e.g. Neuron, Early pregnancy factor, Doxorubicin, rs2476601, IL1A, Allergy to pollen)
Bookmark Forward

Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment.

Valentina Gerussi, Tania Petersen, Isabelle Bonnet, Alexandra Aubry, Marwa Bachir, Esther Gyde, Florence Morel, Corentin Poignon, Brigitte Rached, Valérie Pourcher, Christophe Rioux, Dorothée Vallois, Nicolas Veziris, Jérôme Robert, Lorenzo Guglielmetti

Emerging infectious diseases 2025 Mar


filter terms:
  • adult (1)
  • antitubercular agents (2)
  • female (1)
  • humans (1)
  • isoniazid (6)
  • multidrug- resistant tuberculosis (4)
  • mycobacterium tuberculosis (1)
  • tuberculosis (1)
    • Sizes of these terms reflect their relevance to your search.

    High-dose isoniazid is recommended to treat multidrug-resistant tuberculosis (MDR TB). Among 958 MDR TB isolates identified in France during 2008-2022, 93.1% exhibited high-level isoniazid resistance, and molecular testing showed limited diagnostic accuracy in predicting resistance. Clinicians should reconsider using high-dose isoniazid in MDR TB treatment because of suboptimal effect and toxicity concerns.

    Citation

    Valentina Gerussi, Tania Petersen, Isabelle Bonnet, Alexandra Aubry, Marwa Bachir, Esther Gyde, Florence Morel, Corentin Poignon, Brigitte Rached, Valérie Pourcher, Christophe Rioux, Dorothée Vallois, Nicolas Veziris, Jérôme Robert, Lorenzo Guglielmetti. Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment. Emerging infectious diseases. 2025 Mar;31(3):633-636

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 40023825

    View Full Text
    • Copyright © 2025 Illumina Inc. All rights reserved.